Drug intelligence / Profile preview

PAS-001

Development stage: Unknown
Lead developer: Pasithea Therapeutics
Modality: Small Molecules

Overview

PAS-001 is an investigational small molecule drug developed by Pasithea Therapeutics targeting the C4A family of the complement system as a modulator. Its primary research focus is as a potential treatment for schizophrenia and possibly other nervous system diseases. The drug is still in the discovery phase, with no reported progression into clinical trials as of May 2025. Its mechanism of action is described as modulation of complement C4A (Rodgers blood group) activity, which may impact immunological processes relevant in psychiatric disorders[5].

Targets

C4A (Complement component 4A)

Beyond the preview

Go deeper on PAS-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PAS-001.

Explore the full profile